0001415889-24-008772.txt : 20240320 0001415889-24-008772.hdr.sgml : 20240320 20240320180031 ACCESSION NUMBER: 0001415889-24-008772 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240319 FILED AS OF DATE: 20240320 DATE AS OF CHANGE: 20240320 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Verwijs Marinus CENTRAL INDEX KEY: 0001916553 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40544 FILM NUMBER: 24768834 MAIL ADDRESS: STREET 1: C/O AEROVATE THERAPEUTICS, INC. STREET 2: 200 BERKELEY STREET, FLOOR 18 CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aerovate Therapeutics, Inc. CENTRAL INDEX KEY: 0001798749 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 831377888 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 930 WINTER STREET STREET 2: SUITE M-500 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-443-2400 MAIL ADDRESS: STREET 1: 930 WINTER STREET STREET 2: SUITE M-500 CITY: WALTHAM STATE: MA ZIP: 02451 4 1 form4-03202024_060317.xml X0508 4 2024-03-19 0001798749 Aerovate Therapeutics, Inc. AVTE 0001916553 Verwijs Marinus C/O AEROVATE THERAPEUTICS, INC. 930 WINTER STREET, SUITE M-500 WALTHAM MA 02451 false true false false CHIEF TECHNICAL OFFICER 1 Common Stock 2024-03-19 4 M 0 5300 14.59 A 5300 D Common Stock 2024-03-19 4 S 0 2536 25.6779 D 2764 D Common Stock 2024-03-19 4 S 0 2764 26.4558 D 0 D Stock Option (Right to Buy) 14.59 2024-03-19 4 M 0 5300 0 D 2032-03-20 Common Stock 5300 84700 D This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2023. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.255 to $26.125, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.30 to $26.71, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. 25% of this option vested and became exercisable on March 21, 2023, with the remainder vesting in 36 substantially equal monthly installments thereafter. /s/ George A Eldridge, Attorney-in-Fact 2024-03-20